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Available online 2 July 2016Oncolytic viruses (OV) are replicating viral therapeutics for the treatment of cancer and have been in laboratory
development for about twenty years. Recently, the FDA approved Imlygic, a herpes virus based therapeutic for
the treatment of melanoma and thus OVs have entered a new era where they are a weapon in the armament
of the oncologist. OVs are unique therapeutics with multiple mechanisms of therapeutic activity. The exact
path for their development and eventual uptake bypharmaceutical companies is somewhat cloudedby anuncer-
tain identity. Are they vaccines, tumour lysing therapeutics, inducers of innate immunity, gene therapy vectors,
anti-vascular agents or all of the above? Should they be developed as stand-alone loco-regional therapeutics, sys-
temically delivered tumour hunters or immune modulators best tested as combination therapeutics? We sum-
marize data here supporting the idea, depending upon the virus, that OVs can be any or all of these things.
Pursuing a “one-size ﬁts all” approach is counter-productive to their clinical development and instead as a
ﬁeld we should build on the strengths of individual virus platforms.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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There is a great deal of intellectual appeal in the concept of oncolytic
viruses (OVs) as programmable biological machines that target, repli-
cate in and ultimately destroy cancer cells. OVs have been underr Therapeutics, Ottawa Hospital
anada.
. This is an open access article underdevelopment in academic laboratories around the world for in excess
of 20 years but like any new therapeutic idea, OVs have faced an uphill
battle in achieving clinical validation and ultimately commercial accep-
tance. Only recently has the herpes virus based therapeutic, Imlygic
(talimogene laherparepvec, Amgen), broken through the “glass ceiling”
and emerged as an FDA and EMEA approved treatment for advanced
melanoma. This has led to a virtual stampede (by OV standards) of
small biotechnology companies vying to produce the next “Imylgic”, at
last count in excess of twenty burgeoning companies. According tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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phase III trials, nine in phase II, at least eight in phase I development
and the number will increase by the end of the year.
2. Oncolytic Viruses Have Arrived: ButWhat Are They?What Do They
Do?
OVs are multi-mechanistic therapeutics but their versatility has left
them suffering from an identity crisis - are they in situ vaccines, system-
ically administered cancer killers, potent oncolytic vaccines, anti-vascu-
lar agents, gene therapy vectors, or loco-regional adjuvants that
stimulate innate immune reactions? The reality is OVs can be any or
all of these things depending upon the virus platform under consider-
ation and the clinical indication (Leveille et al., 2011; Breitbach et al.,
2013; Melcher et al., 2011; Russell et al., 2012; Kelly and Russell,
2007; Russell et al., 2014; Kirn and Thorne, 2009; Kaufman et al.,
2015; Lichty et al., 2014). With our advanced understanding of themo-
lecular biology of cancers and virus:host interactions we are positioned
to rapidly create tailored therapeutics with multiple mechanisms of ac-
tion. Let's ﬁrst consider OVs as loco-regional in situ vaccines.
3. Imlygic: The Case for an Oncolytic Virus In Situ Vaccine
Since the insightful development of Coley's toxin over a century
ago, there have been numerous strategies developed to stimulate a
cancer patient's immune response against their own tumour
(Pierce et al., 2015; van der Burg et al., 2016). Much like Coley's
toxin, these strategies provided provocative responses in small trials
of select patients but for the most part, failed when tested more
widely. These “adjuvant and vaccine” therapies were designed to
drive immune responses against so-called tumour antigens includ-
ing cancer testis antigens, over-expressed tissue speciﬁc proteins,
aberrant post-translational modiﬁcations and neoepitopes created
during malignant evolution (Rosenberg et al., 2004). The reasons
for these frustrating failures were revealed by fundamental research
into the signaling pathways that regulate our immune systems. We
are genetically programmed to rapidly mount immune responses
to invading pathogens but at the same time, just as quickly dampen
immune responses to avoid acute cytokine storm toxicity and auto-
immunity. These homeostatic mechanisms are controlled in large
part by integrated immune checkpoint networks and in the tumour
microenvironment, these critical regulatory pathways are usurped
providing malignant cells with an immunosuppressive cloak
(Pardoll, 2012). Given that therapeutics have now been approved
that block this negative feedback loop, there is a renewed interest
in in situ vaccines and other approaches that may show enhanced ac-
tivity upon combinationwith immune checkpoint inhibitors (ICIs). For
instance, so-called “viral mimetics” like imiquimod (Vasilakos and
Tomai, 2013) and “sting agonists” are in development (Deng et al.,
2014; Fu et al., 2015; Wang et al., 2016) in an attempt to re-polarize
the tumour microenvironment making it immunologically respon-
sive and like Coley's toxin, facilitating an environment conducive to
creating an in situ vaccine.
4. Heating Up Immunologically Cold Tumours With an Oncolytic
Virus
As discussed our immune systems have evolved elaborate mecha-
nisms to react against invading pathogens and rapidly mount immune
responses to eliminate the pathogen and in some instances, the cells
they infect. OVs are natural pathogens that have been selected or de-
signed to speciﬁcally infect and destroy cancer cells. Tumour cell infec-
tion by an OV leads to an inﬂammatory response with localized
production of cytokines that favour the elaboration of an immune re-
sponse (Breitbach et al., 2007; Worschech et al., 2009). At the same
time, it is thought that virus mediated tumour lysis leads to theliberation of tumour associated antigens and/or mutant proteins that
have arisen during tumour evolution. Indeed Woller and colleagues
have shown in a mouse tumour model that oncolytic adenovirus tu-
mour therapy stimulates therapeutically beneﬁcial immune responses
against mutanome peptides (Woller et al., 2015).
Imlygic has provided the ﬁrst convincing humandata supporting the
idea that direct tumour lysis by a replicating virus can locally stimulate
sufﬁcient anti-tumour immune responses to provide systemic, long
lasting, cancer killing immune responses in advanced cancer patients
(Senzer et al., 2009; Kaufman et al., 2010; Andtbacka et al., 2015). This
product was administered multiple times via direct intratumoral injec-
tion and, in the OPTiM pivotal phase III trial as a mono-therapy, gener-
ated durable responses in over 16% of patients (Andtbacka et al.,
2015). At the time of FDA approval, Imlygic was shown to have im-
proved overall survival versus treatment with GM-CSF (p= 0.049, Haz-
ard Ratio = 0.79). In earlier phase I and II studies, Imlygic therapy was
shown to increase T cell inﬁltration into tumours and generate a sys-
temic immune response against tumour associated antigens like
MART1 (Kaufman et al., 2010).5. Timing is Everything! –Making a Good Therapeutic Great!
In a follow-up retrospective analysis of the OPTiM trial, Imlygic was
found to generate complete responses in 17% of advanced cancer pa-
tients thus providing the oncologistwith a newmonotherapy treatment
option for melanoma patients. However the better news is that Imlygic
arrived on the scene coincident with the tremendous clinical excite-
ment surrounding the approval of antibodies targeting immune check-
point molecules (e.g. Yervoy [Bristol-Meyers Squibb] directed against
CTLA4 and Keytruda [Merck], Opdivo [Bristol-Meyers Squibb] against
PD1). Asmentioned above, these immune checkpoint inhibitor antibod-
ies interrupt negative feedback systems within the tumour bed effec-
tively “taking the brakes off” pre-existing anti-tumour immune
responses (Pardoll, 2012) and can create durable responses that are
on a trajectory for cure as monotherapies in as many as 20% of patients
(Topalian et al., 2012) (depending upon the indication). For the remain-
ing 80% of patients it appears that a lack of anti-tumour immune re-
sponses or other immune suppressive aspects of the tumour
microenvironment still need to be corrected before immune checkpoint
inhibitors (ICIs) can provide beneﬁt. Infection of tumours by an OV trig-
gers induction of anti-tumour immunity and recruitment of T cells to tu-
mours; addition of the ICI ensures those T cells remain active (Fig. 1).
Indeed, Imlygic seems to be a perfect complement to ICIs and as pre-
dicted, in ongoing phase I studies Imlygic used in combination with
Yervoy signiﬁcantly increases durable response rates in melanoma pa-
tients over what would be expected from either agent alone, perhaps
providing beneﬁt in as many as 50% of patients treated including
many with signiﬁcant tumour burden (Puzanov et al., 2016). The anti-
PD1 immune checkpoint inhibitor Keytruda is also being studied in
combination with Imlygic in patients with melanoma and head and
neck cancer (NCT02263508, NCT02626000). Thus Imlygic continues to
provide clinical evidence for the “in situ vaccine” paradigm for oncolytic
viruses demonstrating that virus oncolysis, even in a limited number of
tumours, can generate systemic anti-tumour immunity. These early
clinical results are encouraging but they also raise a number of ques-
tions.Why do only aminority of patients experience complete response
on Imlygic monotherapy even though direct injection of tumours
should be the optimalway to deliver amaximumdose of virus to the tu-
mour bed? Are themajority of tumours injected by this route onlymar-
ginally infectable? Could amore potent OV havemore profound tumour
lytic and in situ vaccine effect? Can outcomes be improved with opti-
mized Imlygic dosing strategies? Are uninfected tumours in the major-
ity of patients resistant to the systemic immunity that local Imlygic
therapy initiates? Will other tumour indications beside melanoma re-
spond systemically after locoregional virus therapy?
Fig. 1.Oncolytic viruses sensitize tumours to immune checkpoint inhibitors. By ‘releasing the brakes’ on T cells, immune checkpoint inhibitors rely on a pre-existing anti-tumour immune
response for clinical activity. OV infection of the tumour bed releases tumour antigens and results in T cell recruitment to tumours. These T cells are then ‘un-inhibited’ by immune
checkpoint inhibitor antibodies.
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While Imlygic and several other OV platforms are designed as
loco-regional therapeutics, for a variety of reasons, intravenous ad-
ministration ultimately may be the preferred route of delivery
(Naik et al., 2012). Metastatic or widespread cancers remain for the
most part incurable and thus a therapeutic that can reach and attack
all sites of cancer growth is desirable.We know that tumours are het-
erogeneous and thus an in situ vaccine from a primary tumour may
not be effective in a metastatic lesion. Re-polarization of one tumour
microenvironment may be insufﬁcient - each tumour bed within the
patient may have to be infected to facilitate T cell invasion. Finally,
for pragmatic reasons, therapeutics that can be administered intra-
venously in the clinic are preferred. We have demonstrated that an
oncolytic vaccinia virus can be delivered by intravenous infusion
and spread within the tumour bed (Breitbach et al., 2011a). Similar
ﬁndings have now been made with the chimeric adenovirus
Enandenotucirev in colon cancer patients (PsiOxus unpublished
ﬁndings). In a phase I study an oncolytic measles virus expressing
the sodium iodide symporter was delivered to multiple metastatic
lesions within myelomas patients and led to a complete and durable
response in one patient after intravenous delivery (Russell et al.,
2014). Successful delivery of measles OV seemed only to occur in pa-
tients who lacked neutralizing antibodies (NAbs) against the virus.
Interestingly for some viruses, intravenous delivery can occur even
in the presence of NAbs. Reolysin, can apparently bypass NAbs by
riding on immune cells in the circulation which eventually trafﬁc
into the tumour and deposit their viral cargo (Adair et al., 2012). De-
spite these ﬁndings, very limited clinical activity has been observed
in early studies using intravenous OV delivery. However the ﬁnding
that the majority of Imlygic's therapeutic beneﬁt appears to be
unmaskedwhen combined with ICIs suggests that combination ther-
apy employing intravenously administered OVs and ICIs may hold
great promise. Currently both Reolysin and Enadenotucirev are
being tested intravenously in combination with Keytruda
(NCT02620423, NCT02636036).
7. Best of BothWorlds – An Oncolytic Virus That Doubles as an Anti-
cancer Vaccine
Though the potential of OVs to induce therapeutic immune re-
sponses against cancer antigens has been demonstrated with Imlygic,
data from preclinical models and patients suggests that the natural in-
duction of anti-tumour immunity is ‘hit &miss’with a pure oncolytic ap-
proach (Andtbacka et al., 2015). It appears that only in a minority ofcases is the infection of the tumour bed and the concomitant release
of endogenous tumour antigens sufﬁcient to trigger a complete tumour
response. Rather than hoping an immune response is induced with a
pure oncolytic approach, we have used the ability of some OVs to en-
code transgenes and have created an oncolytic virus vaccine. In this
strategy, all the beneﬁts of an OV remain – including direct tumour
lysis, transformation of the tumour immune microenvironment, attack
on tumour vasculature and the release of endogenous tumour antigens
– but in addition, a “supercharged” immune response is directed against
a speciﬁc antigen or antigens expressed on the patient's cancer cells.
This is accomplished by using heterologous prime:boost technology, a
method that has been shown to be effective in the setting of infectious
disease vaccines (Lu, 2009). Essentially two immunologically distinct vi-
ruses expressing the same antigen are used in sequence ﬁrst to prime
and then to boost an immune response against the encoded antigen.
For instance, in cancer models an adenovirus vaccine has been used to
locally prime an immune response against a deﬁned tumour cell anti-
gen. This is followed by systemic therapy with an oncolytic virus
encoding the same antigen. This strategy has proven to induce anti-tu-
mour immune responses at unprecedented levels (e.g. 30% of circulating
T cells (Pol et al., 2014)). The generation of large anti-tumour antigen
immune responses in combination with tumour oncolysis creates the
perfect immunological storm within the tumour leading to profound
therapeutic effects in metastatic tumour models. Furthermore, the
mechanism by which the OV expressing a tumour antigen (in this
case Maraba MG1 expressing the melanoma associated antigen
dopachrome tautomerase [DCT]) induces immune responses of large
magnitude has been recently elucidated (Bridle et al., 2016). Systemic
administration of the OV vaccine – of course a very unique route of ad-
ministration by which to vaccinate – results in infection of follicular B
cells in the spleen. This is an abortive infection and virally encoded pro-
teins (including DCT) are expressed transiently. This antigen is passed
on to dendritic cells which present antigen to central memory T cells
(TCM). These antigen presenting cells reside in a privileged site as effec-
tor T cells (TEFF) do not enter the splenic follicle (Fig. 2). This allows for
administration of the oncolytic boost shortly after the priming vaccina-
tionwhich is important in the context of treating advanced cancerwhen
there is no time to wait for the TEFF cells generated during the priming
vaccination to have cleared. Coincidentally, by utilizing an OV as a vac-
cine vector that is administered intravenously, this unique biology
explaining the dramatic induction of anti-tumour immunity could be
uncovered.
An ongoing phase I/II trial (NCT02285816) is testing this two virus
oncolytic vaccine approach in solid tumours expressing the MAGE-A3
tumour antigen.
Fig. 2.MechanismofMG1 immune boost. The oncolytic virusMG1expressing a tumour associated antigen transiently infects B cells in the splenic follicle. Antigens expressed on these cells
are transferred to follicular dendritic cells that present antigen to TCM cells. The splenic follicles are immune privileged sites as TEFF cells can not enter. Therefore, follicular dendritic cells are
protected from TEFF cell killing, a negative feedback loop (Bridle et al., 2016). This provides a mechanism for the large anti-tumour immune responses observed following treatment with
MG1 expressing a tumour antigen (Pol et al., 2014).
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Microenvironment
The immune suppressive microenvironment that supports malig-
nant cell growth is a signiﬁcant hurdle to successful therapeutic inter-
vention. Aside from their direct anti-tumour activity, OVs on their
own through the induction of acute localized inﬂammation, have the ca-
pacity to perturb the tumour niche in a way that favours innate and im-
mune attack. This occurs by the production of inﬂammatory cytokines
within the tumour milieu from the infected tumour cell (Breitbach et
al., 2007) or as a result of pro-active programming of the virus with im-
mune stimulating cytokines (Li et al., 2011; Patel et al., 2015; Kim et al.,
2006). Recently we and others discovered that cytokines like TGF-β
which are commonly expressed within the tumourmicro-environment
(TME) and suppress immune responses also sensitize cells foundwithin
the tumour microenvironment (e.g. cancer associated ﬁbroblasts or
CAFs) to OV infection (Ilkow et al., 2015; Han et al., 2015). Similarly
FGF-2 expression by CAFs can promote infection of neighboring tumour
cells. Thus immune suppressive cytokines produced within the malig-
nancy can paradoxically create a tumour microenvironment that facili-
tates OV infection and in turn creates a pro-inﬂammatory setting (Ilkow
et al., 2015). Shouldwe consider transiently co-administering particular
cytokines with OVs to jumpstart or promote tumour infection?
Another common feature of the TME is a disorganized supporting tu-
mour vasculature (Fisher et al., 2016). This is in large part caused by
pathological expression of vascular endothelial growth factor (VEGF)
which is both immune suppressive and promotes the growth of
neovasculature. Recently we discovered that there is cross talk between
signaling pathways driven by VEGF and interferon with the transcrip-
tional repressor PRD1/BF1 mediating down-regulation of anti-viral re-
sponses in VEGF treated endothelial cells (Arulanandam et al., 2015).
These ﬁndings suggest that vascular endothelial cells found within the
TME may also be targets for OV infection and destruction. Of course
whether an OV can infect and destroy tumour vasculature will be de-
pendent upon both this VEGFmediated pro-viral state and also if the en-
dothelial cells express the receptor for a particular OV platform. For
viruses like rhabdovirus and poxviruses which have ubiquitouslyexpressed cell receptors attack of tumour vasculature can be readily de-
tected (Breitbach et al., 2013; Kirn et al., 2007; Breitbach et al., 2007,
2011b) in both animal models and cancer patients. Other viruses
which have tissue speciﬁc receptors will not be able to carry out this
same form of anti-tumour attack.
9. Future Directions
Though there has been plenty of investigation into how best to de-
sign oncolytic viruses to attack tumours, it is difﬁcult to determine a
priori in a heterogeneous patient population which of an OV's multiple
mechanisms of action is most critical to therapeutic efﬁcacy. There is lit-
tle doubt that in some animal tumour models (Naik et al., 2012) and
likely some patients (Russell et al., 2014), the pure oncolytic activity of
an OV may be sufﬁcient to cause therapeutic beneﬁt. In other mouse
models where it is possible to rigorously test, oncolysis on its own is in-
sufﬁcient and engagement of the immune system is critical for thera-
peutic beneﬁt (Pol et al., 2014). It seems reasonable to expect in the
human cancer patient population it will be best to attack the tumour
with “guns blazing” and use all aspects of the OV armament to advan-
tage. In our view, likely multiple OVs optimally designed to lyse cancer
cells, stimulate local inﬂammatory responses, synergize with emerging
immune modulating therapies and delivery therapeutic payloads may
be necessary to gain maximum therapeutic beneﬁt from the platform.
In pre-clinical models we have shown it is possible to engineer co-oper-
ative OVs that can synergistically interact to attack cancers for therapeu-
tic gain (Le Boeuf et al., 2010).
Certainly the jury is still out on the bestway to deliver OVs and argu-
ments can be made for either loco-regional or systemic administration.
Indeed theﬂexibility arounddeliveringOVs bydifferent routes, depend-
ing on the clinical setting, may be an advantage over more traditional
therapeutic modalities. For instance, we could envision administering
OVs ﬁrst by a series of intravenous infusions to ensure maximum distri-
bution of the OV to all metastatic sites followed by multiple
intratumoral in situ vaccine boosts. This type of administration regimen
has already been piloted with an oncolytic vaccinia virus
(NCT01387555, NCT01171651).
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• Will loco-regional therapywith oncolytic viruses be sufﬁcient tomeet
their therapeutic potential?
• Is therapeutically effective systemic delivery an achievable goal?
• What new strategies can be developed to disrupt/repolarize the tu-
mour microenvironment using the biological properties of oncolytic
viruses?
• Given the rapidly changing immuno-oncology landscape, should
oncolytic viruses be developed as primarily combination
therapeutics?
11. Search Strategy and Selection Criteria
Data for this Reviewwere identiﬁed by searches of PubMed, and ref-
erences from relevant articles using the search terms “oncolytic virus-
es”, “immune checkpoint inhibitor”, “immune modulation”, “tumour
vasculature”, “cancer vaccines”, “immune adjuvants”, “in situ vaccine”
and “tumour microenvironment”. We included reference to one non-
peer reviewed opinion article in Biocentury.
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